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BACKGROUND
Cardiovascular morbidity and mortality are higher among patients with type 2 
diabetes, particularly those with concomitant cardiovascular diseases, than in 
most other populations. We assessed the effects of lixisenatide, a glucagon-like 
peptide 1–receptor agonist, on cardiovascular outcomes in patients with type 2 
diabetes who had had a recent acute coronary event.
METHODS
We randomly assigned patients with type 2 diabetes who had had a myocardial 
infarction or who had been hospitalized for unstable angina within the previous 
180 days to receive lixisenatide or placebo in addition to locally determined stan-
dards of care. The trial was designed with adequate statistical power to assess 
whether lixisenatide was noninferior as well as superior to placebo, as defined by 
an upper boundary of the 95% confidence interval for the hazard ratio of less than 
1.3 and 1.0, respectively, for the primary composite end point of cardiovascular 
death, myocardial infarction, stroke, or hospitalization for unstable angina.
RESULTS
The 6068 patients who underwent randomization were followed for a median of 
25 months. A primary end-point event occurred in 406 patients (13.4%) in the 
lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 
95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of 
lixisenatide to placebo (P<0.001) but did not show superiority (P = 0.81). There were 
no significant between-group differences in the rate of hospitalization for heart 
failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate 
of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated 
with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, 
pancreatic neoplasms, or allergic reactions than was placebo.
CONCLUSIONS
In patients with type 2 diabetes and a recent acute coronary syndrome, the addi-
tion of lixisenatide to usual care did not significantly alter the rate of major car-
diovascular events or other serious adverse events. (Funded by Sanofi; ELIXA 
ClinicalTrials.gov number, NCT01147250.)
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Randomized trials involving pa-tients with new or established type 2 dia-betes have shown that improved glucose 
control reduces the risk of microvascular com-
plications,1-3 with modest cardiovascular bene-
fits suggested by meta-analyses and extended 
follow-up of clinical trials.4-7 However, various 
studies indicate that, despite being effective in 
lowering the glucose and glycated hemoglobin 
levels, some hypoglycemic medications may in-
crease, rather than reduce, the risk of cardio-
vascular events.8-10 These unexpected findings 
prompted the reexamination of the regulatory 
approval processes for new antidiabetic thera-
pies, which had been based primarily on the 
surrogate measure of glucose lowering with 
limited clinical-outcomes data. Since 2008, reg-
ulatory agencies have required robust cardiovas-
cular-outcome data from randomized, controlled 
trials in order to grant and sustain approvals of 
drugs or biologic agents for the treatment or 
prevention of diabetes mellitus.11-13
Glucagon-like peptide 1 (GLP-1)–receptor ago-
nists are a class of parenteral glucose-lowering 
drugs that activate the receptor for the endoge-
nous incretin GLP-1. These drugs lower glucose 
levels by inhibiting the secretion of glucagon, 
promoting the release of insulin in response to 
hyperglycemia, slowing gastric emptying, and 
augmenting satiety.14 On the basis of some evi-
dence of cardioprotection in preliminary studies 
in animal models15,16 and in pilot studies of myo-
cardial ischemia17,18 and heart failure in hu-
mans,19 it was postulated20,21 that in addition to 
improving glycemic control and promoting weight 
loss, GLP-1–receptor agonists may improve car-
diovascular outcomes.
Lixisenatide, a once-daily GLP-1–receptor ago-
nist, is effective in reducing the glycated hemo-
globin level in patients with type 2 diabetes by 
lowering both the fasting and the postprandial 
blood glucose levels.22-25 However, the studies 
showing such glycemic control and other favorable 
metabolic effects of lixisenatide were not designed 
to accrue sufficient clinical events to adequately 
show its cardiovascular safety. Although lixisena-
tide and several other GLP-1–receptor agonists 
are approved in many countries for use as glu-
cose-lowering agents in patients with type 2 dia-
betes, large cardiovascular-outcome trials with 
any agent in this class have been lacking.
Me thods
Study Design
The Evaluation of Lixisenatide in Acute Coronary 
Syndrome (ELIXA) trial was a multicenter, ran-
domized, double-blind, placebo-controlled trial 
involving patients with type 2 diabetes who had 
had a recent acute coronary syndrome. The trial 
was designed to assess the effects of lixisenatide 
on cardiovascular morbidity and mortality. De-
tails of the trial design and the demographic 
and clinical characteristics of the patients at 
baseline have been reported previously.26 The 
study protocol, available with the full text of this 
article at NEJM.org, was designed by the execu-
tive committee, which also oversaw the conduct 
of the trial (see the Supplementary Appendix, 
available at NEJM.org).
The chair of the executive committee wrote 
the first draft of the manuscript, and all the 
coauthors contributed to the subsequent revi-
sions. Data were analyzed and confirmed at two 
statistical centers (one at the sponsor’s location 
and one at Brigham and Women’s Hospital). Each 
author could query the database by requesting 
specific analyses or clarifications of definitions. 
All the authors edited and approved the manu-
script and assume full responsibility for the 
accuracy and completeness of the data and for 
the fidelity of this report to the study protocol, 
which was approved by the appropriate national 
and institutional regulatory and ethics boards. All 
the patients provided written informed consent.
Study Patients
Eligible patients had type 2 diabetes and had 
had an acute coronary event within 180 days 
before screening. Major exclusion criteria were 
an age of less than 30 years, percutaneous coro-
nary intervention within the previous 15 days, 
coronary-artery bypass graft surgery for the 
qualifying event, planned coronary revasculariza-
tion procedure within 90 days after screening, an 
estimated glomerular filtration rate (eGFR) of 
less than 30 ml per minute per 1.73 m2 of body-
surface area, a glycated hemoglobin level of less 
than 5.5% or more than 11.0%, or an inability 
to provide written informed consent.26 Before 
randomization, there was a 1-week run-in period 
during which eligible consenting patients were 
trained in the self-administration of daily subcu-
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taneous injections of unblinded placebo, with 
the volume matched to that of the injections 
they would receive after randomization.
Study Interventions
Patients were randomly assigned, in a double-
blind manner, to once-daily subcutaneous injec-
tions of lixisenatide or volume-matched placebo. 
Randomization was performed with the use of a 
centralized assignment system. A starting dose 
of 10 μg of lixisenatide per day or volume-
matched placebo was administered during the 
first 2 weeks and then increased, at the investi-
gator’s discretion, to a maximum dose of 20 μg 
of lixisenatide per day or volume-matched pla-
cebo. Glycemic control was managed by the in-
vestigators in accordance with local clinical prac-
tice guidelines by the adjustment of concomitant 
glucose-lowering agents or the addition of new 
antidiabetic medications with the exception of 
other incretin therapies. This approach was ex-
pected to yield similar glycemic control in the 
two study groups.
Study End Points
The primary end point in the time-to-event 
analysis was a composite of the first occurrence 
of any of the following: death from cardiovascu-
lar causes, nonfatal myocardial infarction, non-
fatal stroke, or hospitalization for unstable an-
gina. Secondary end points included a composite 
of the primary end point or hospitalization for 
heart failure and a composite of the primary end 
point, hospitalization for heart failure, or coro-
nary revascularization procedures. All-cause mor-
tality and the rates of the components of each of 
the composite end points were examined.
Changes in the glycated hemoglobin level, 
urinary albumin-to-creatinine ratio, body weight, 
heart rate, and blood pressure were evaluated. 
Safety end points, including the incidence of 
hypoglycemia and severe hypoglycemia (requiring 
the assistance of another person), pancreatitis, 
cancer, and systemic allergic reactions, were as-
sessed in patients who underwent randomiza-
tion and received at least one dose of lixisenatide 
or placebo. Separate independent committees 
whose members were unaware of the study-
group assignments adjudicated potential cardio-
vascular, pancreatic, and allergic events (see the 
Supplementary Appendix).
Study Oversight
The data and safety monitoring committee, 
whose members had access to unblinded data, 
monitored the safety of the participants. When 
144 adjudicated primary end-point events had 
occurred, the data and safety monitoring com-
mittee reviewed a prespecified, independently 
performed analysis of the unblinded data and 
informed the executive committee and the spon-
sor that the upper boundary of the resulting 96% 
confidence interval of the hazard ratio for the 
comparison of lixisenatide with placebo was less 
than 1.8 (see the Supplementary Appendix).9,11,27 
At that time, a group from the sponsor, which 
was not in communication with the ELIXA team, 
prepared and subsequently filed a New Drug Ap-
plication with the Food and Drug Administra-
tion, which was later withdrawn to avoid public 
disclosure of preliminary data.
Statistical Analysis
The primary analysis was conducted in the inten-
tion-to-treat population with the use of the Cox 
proportional-hazards model, with study group 
and geographic region as the covariates, to esti-
mate the hazard ratio for the comparison of 
lixisenatide with placebo. The noninferiority of 
lixisenatide to placebo would be shown if the 
upper boundary of the 95% confidence interval 
of the hazard ratio was less than 1.3 and the 
superiority would be shown if the upper bound-
ary was less than 1.0.11 The P values for the tests 
of noninferiority and superiority are derived from 
the Cox proportional-hazards model.
The trial was event-driven. We estimated that 
6000 patients would need to be enrolled for us 
to observe 844 primary end-point events, which 
would provide the study with 96% power to 
show noninferiority, assuming a true hazard 
ratio of 1.0, and with 90% power to show supe-
riority, assuming a true hazard ratio of 0.80. 
More complete details regarding sample-size 
assumptions have been published previously.26
Sensitivity analyses were conducted in which 
events that occurred more than 30 days after 
the discontinuation of lixisenatide or placebo 
were excluded; in addition, a post hoc Cox 
proportional-hazards analysis was conducted 
with a model that was adjusted for nominally 
significant baseline imbalances. Postbaseline 
measures were analyzed with the use of non-
The New England Journal of Medicine 
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Characteristic Placebo (N = 3034) Lixisenatide (N = 3034)
Age — yr 60.6±9.6 59.9±9.7
Age ≥65 yr — no. (%) 1040 (34.3) 1003 (33.1)
Female sex — no. (%) 938 (30.9) 923 (30.4)
Duration of diabetes — yr 9.4±8.3 9.2±8.2
Glycated hemoglobin — % 7.6±1.3 7.7±1.3
Retinopathy — no. (%) 331 (10.9) 320 (10.5)
Neuropathy — no. (%) 498 (16.4) 512 (16.9)
Body weight — kg 85.1±19.6 84.6±19.2
Body­mass index† 30.2±5.8 30.1±5.6
Race — no. (%)‡
Asian 367 (12.1) 404 (13.3)
Black 103 (3.4) 118 (3.9)
Other 246 (8.1) 254 (8.4)
White 2318 (76.4) 2258 (74.4)
Hispanic ethnic group — no. (%)‡ 903 (29.8) 865 (28.5)
Geographic region — no. (%)
Africa or Near East 142 (4.7) 154 (5.1)
Asia Pacific 329 (10.8) 374 (12.3)
Eastern Europe 811 (26.7) 776 (25.6)
North America 403 (13.3) 404 (13.3)
South or Central America 972 (32.0) 972 (32.0)
Western Europe 377 (12.4) 354 (11.7)
Current smoking — no. (%) 354 (11.7) 355 (11.7)
Myocardial infarction before index ACS — no. (%) 672 (22.1) 672 (22.1)
Medical history at randomization — no. (%)
Hypertension 2340 (77.1) 2295 (75.6)
Percutaneous coronary intervention 2027 (66.8) 2052 (67.6)
Coronary­artery bypass grafting 249 (8.2) 258 (8.5)
Heart failure 676 (22.3) 682 (22.5)
Stroke 188 (6.2) 143 (4.7)
Peripheral arterial disease§ 229 (7.5) 237 (7.8)
Atrial fibrillation 190 (6.3) 176 (5.8)
Systolic blood pressure — mm Hg 130±17 129±17
Heart rate — beats/min 70.2±9.9 70.2±10.1
HDL cholesterol — mg/dl 42.9±10.9 43.0±10.8
LDL cholesterol — mg/dl 78.2±35.2 78.8±35.4
eGFR — ml/min/1.73 m2 75.2±21.4 76.7±21.3
Qualifying ACS event — no. (%)
NSTEMI 1183 (39.0) 1165 (38.4)
STEMI 1317 (43.4) 1349 (44.5)
Unstable angina 528 (17.4) 514 (16.9)
Unclassified 6 (0.2) 6 (0.2)
Table 1. Characteristics of the Patients at Baseline.*
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prespecified repeated-measures, mixed-effects 
linear regression models with patient-specific 
random-intercept terms and an independent 
within-patient residual covariance structure. 
Study group and visit were included in the 
model as factors, and baseline value was in-
cluded as a covariate. Other comparisons were 
performed with the use of Student’s t-tests, 
Wilcoxon rank-sum tests, and chi-square tests 
and were not prespecified or adjusted for mul-
tiplicity. Summary statistics include all avail-
able postbaseline data, whereas the figures 
exclude data beyond 40 months of follow-up 
(<10% of patients had longer follow-up).
R esult s
Patients and Interventions
Between July 9, 2010, and August 2, 2013, we 
enrolled 6068 patients from 49 countries and 
randomly assigned 3034 patients to lixisenatide 
and 3034 to placebo. All but 5 patients (3 patients 
in the lixisenatide group and 2 in the placebo 
group) received at least one dose of lixisenatide 
or placebo.
At the recommendation of the data and safety 
monitoring committee, the study went to com-
pletion. On the basis of projections made by the 
sponsor and shared with the executive commit-
tee without knowledge of the study-group assign-
ments, it was estimated that the initiation of 
end-of-study visits on November 11, 2014, would 
allow for the observation of the prespecified 
number of adjudicated events. The last patient 
visit occurred on February 11, 2015. Overall, we 
observed that 805 patients had a confirmed pri-
mary end-point event, which provided the study 
with more than 95% power for the test of non-
inferiority and more than 88% power for the test 
of superiority.
The characteristics of the study groups were 
generally balanced at baseline (Table 1, and Ta-
ble S1 in the Supplementary Appendix). Nomi-
nally significant between-group differences were 
observed in 4 of the 35 baseline comparisons 
(those regarding age, eGFR, glycated hemoglo-
bin level, and prior stroke) (Table 1, and Table S1 
in the Supplementary Appendix).
The median follow-up was 25 months in each 
study group. Among patients who did not die, 
96.3% of the patients in the lixisenatide group 
and 96.1% of those in the placebo group com-
pleted the study. Vital status was ascertained at 
the end of the study in all but 29 patients (1.0%) 
in the lixisenatide group and in all but 42 (1.4%) 
in the placebo group.
The mean duration of exposure to study medi-
cation was 690 days in the lixisenatide group and 
712 days in the placebo group. Excluding the 51 
patients in the lixisenatide group and 41 in the 
placebo group who were taking the study medi-
cation on the day of death, the study medication 
was permanently discontinued in 833 patients 
(27.5%) in the lixisenatide group and in 727 
(24.0%) in the placebo group (P =  0.002). Among 
patients who received at least one dose of lixisena-
tide or placebo, 2591 of 3031 patients (85.5%) in 
the lixisenatide group were taking the maximum 
dose of 20 μg at the time of their last dose of 
lixisenatide, and 2926 of 3032 patients (96.5%) 
Characteristic Placebo (N = 3034) Lixisenatide (N = 3034)
Days from ACS to randomization 72.2±43.9 71.8±43.4
Urinary albumin:creatinine ratio¶
Median 10.5 10.2
Interquartile range 6.0–33.6 6.0–29.6
*  Plus–minus values are means ±SD. There were no significant between­group differences at baseline, except with re­
spect to age (P = 0.005), estimated glomerular filtration rate (eGFR; P = 0.006), glycated hemoglobin level (P = 0.02), and 
prior stroke (P = 0.01). To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. ACS denotes 
acute coronary syndrome, HDL high­density lipoprotein, LDL low­density lipoprotein, NSTEMI non–ST­segment eleva­
tion myocardial infarction, and STEMI ST­segment elevation myocardial infarction.
†  The body­mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race and ethnic group were self­reported.
§  Peripheral arterial disease included amputation due to a cause other than trauma.
¶  Albumin was measured in milligrams and creatinine in grams.
Table 1. (Continued.)
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in the placebo group were taking the volume-
matched equivalent for this maximum dose.
Cardiovascular End Points
The primary end point occurred in 406 patients 
(13.4%) in the lixisenatide group and in 399 
(13.2%) in the placebo group. For this first-
occurrence composite end point in the time-to-
event analysis, the contributions from each com-
ponent event are shown in Table 2. The hazard 
ratio for the primary end point in the lixisena-
tide group as compared with the placebo group 
was 1.02 (95% confidence interval [CI], 0.89 to 
1.17); the upper boundary of the 95% confidence 
interval excluded 1.3 but not 1.0, which showed 
the noninferiority of lixisenatide to placebo 
(P<0.001) but not superiority (P = 0.81) (Fig. 1).
Sensitivity analyses that excluded events oc-
curring more than 30 days after discontinuation 
of lixisenatide or placebo and that were adjusted 
for baseline imbalances produced similar results 
(Table S2 in the Supplementary Appendix). No 
significant study-group interactions were observed 
for the primary end point in the prespecified 
subgroups or in the post hoc subgroups, includ-
ing the subgroup defined according to history or 
no history of heart failure (Fig. S1 in the Supple-
mentary Appendix).
Regarding the separate cardiovascular com-
ponents of the primary end point, the frequency 
of each was similar in the two study groups 
(Table 2). A total of 156 patients in the lixisena-
tide group and 158 in the placebo group died 
from cardiovascular causes (hazard ratio, 0.98; 
95% CI, 0.78 to 1.22), a total of 270 patients in 
the lixisenatide group and 261 in the placebo 
group had a fatal or nonfatal myocardial infarc-
tion (hazard ratio, 1.03; 95% CI, 0.87 to 1.22), a 
total of 67 patients in the lixisenatide group and 
60 in the placebo group had a fatal or nonfatal 
stroke (hazard ratio, 1.12; 95% CI, 0.79 to 1.58), 
and a total of 11 patients in the lixisenatide 
group and 10 in the placebo group were hospi-
talized for unstable angina (hazard ratio, 1.11; 
95% CI, 0.47 to 2.62).
When hospitalization for heart failure was 
added to the primary composite end point, 456 
patients (15.0%) in the lixisenatide group and 
469 (15.5%) in the placebo group had an event 
in this expanded end point (hazard ratio, 0.97; 
95% CI, 0.85 to 1.10). The further addition of 
coronary revascularization procedure to the ex-
panded composite end point resulted in 661 pa-
tients (21.8%) in the lixisenatide group and 659 
(21.7%) in the placebo group having at least one 
of these adjudicated cardiovascular end points 
(hazard ratio, 1.00; 95% CI, 0.90 to 1.11) (Table 2).
As a separate end point, hospitalization for 
heart failure occurred in 122 patients (4.0%) in 
the lixisenatide group and in 127 (4.2%) in the 
placebo group (hazard ratio, 0.96; 95% CI, 0.75 
to 1.23) (Table 2). Death from any cause was 
reported in 211 patients (7.0%) in the lixisena-
tide group and in 223 (7.4%) in the placebo 
group (hazard ratio, 0.94; 95% CI, 0.78 to 1.13) 
(Table 2). Deaths that were adjudicated as having 
resulted from noncardiovascular causes oc-
curred in 46 patients (1.5%) in the lixisenatide 
group and in 58 (1.9%) in the placebo group.
Clinical and Metabolic Effects
Although the management of glucose levels in 
individual patients was at the discretion of the 
treating physicians, the reduction in glycated 
hemoglobin values from baseline to week 12 was 
significantly greater among patients randomly 
assigned to lixisenatide than among those as-
signed to placebo (−0.6 percentage points vs. 
−0.2 percentage points, P<0.001). The between-
group difference (lixisenatide minus placebo) 
Figure 1. Kaplan–Meier Plot of the First Confirmed Primary End-Point Event.
The composite primary end point in the time­to­event analysis was death 
from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, 
or hospitalization for unstable angina. The inset shows the same data on 
an enlarged y axis.
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was sustained, with an average difference across 
all visits of −0.27 percentage points (95% CI, 
−0.31 to −0.22; P<0.001) (Fig. 2). Hypoglycemic 
episodes during the study were reported in 504 
patients (16.6%) in the lixisenatide group and in 
462 (15.2%) in the placebo group (P = 0.14). Seri-
ous hypoglycemic episodes (requiring assistance 
from another person) were numerically less fre-
quent with lixisenatide (14 patients reporting 16 
events) than with placebo (24 patients reporting 
37 events).
A modest but significant between-group dif-
ference in the change in body weight from base-
line was apparent at 12 weeks (−0.6 kg in the 
lixisenatide group vs. −0.0 kg in the placebo group, 
P<0.001). This relative weight difference was 
sustained throughout the follow-up period, with 
an average between-group difference (lixisena-
tide minus placebo) across all visits of −0.7 kg 
(95% CI, −0.9 to −0.5; P<0.001) (Fig. S2 in the 
Supplementary Appendix).
A modest relative difference (lixisenatide minus 
placebo) in systolic blood pressure in the lixisena-
tide group as compared with the placebo group 
was sustained throughout follow-up, with an av-
erage difference across all visits of −0.8 mm Hg 
(95% CI, −1.3 to −0.3) in favor of lixisenatide 
(P = 0.001) (Fig. S3 in the Supplementary Appen-
dix). A small but significant difference in heart 
rate was observed, with, on average, 0.4 more 
beats per minute (95% CI, 0.1 to 0.6) in the lix-
isenatide group than in the placebo group across 
all visits (P = 0.01). This result appeared to be 
due predominantly to an increase of 1 beat per 
minute at weeks 2 and 6 that was not detected 
at later time points (Fig. S4 in the Supplemen-
tary Appendix).
Although the prespecified analysis of the 
percentage change in the urinary albumin-to-
creatinine ratio (with albumin measured in milli-
grams and creatinine measured in grams) from 
baseline to 108 weeks showed a modest differ-
ence in favor of lixisenatide over placebo (24% 
vs. 34%, P = 0.004), the median values at baseline 
(ratio, 10 in each study group) and follow-up 
(ratio, 12 in the lixisenatide group and 13 in the 
placebo group) were clinically similar (Table S3 
in the Supplementary Appendix). In a post hoc 
model that included further adjustment for the 
glycated hemoglobin level as measured at base-
line and at 3 months after randomization, this 
difference was attenuated (P = 0.07) (Table S3 in 
the Supplementary Appendix).
Adverse Events
Adverse events that led to the permanent discon-
tinuation of lixisenatide or placebo occurred in 
347 patients (11.4%) in the lixisenatide group 
and in 217 (7.2%) in the placebo group (P<0.001). 
The most common adverse event leading to dis-
continuation was a gastrointestinal event, which 
was reported in 149 patients (4.9%) in the lix-
isenatide group and in 37 (1.2%) in the placebo 
group (P<0.001) (Table S4 in the Supplementary 
Appendix). Within this category, nausea or vom-
iting accounted for most of the between-group 
difference in the discontinuation of lixisenatide 
or placebo, with 91 patients (3.0%) in the lix-
isenatide group and 11 (0.4%) in the placebo 
group discontinuing because of nausea and 33 
(1.1%) in the lixisenatide group and 5 (0.2%) in 
the placebo group discontinuing because of 
vomiting (P<0.001 for both comparisons).
Serious adverse events were reported in 625 
patients (20.6%) in the lixisenatide group and in 
669 (22.1%) in the placebo group. Serious ad-
verse events that were attributed to the gastro-
intestinal system were reported in 66 patients 
(2.2%) in the lixisenatide group and in 81 (2.7%) 
in the placebo group (Table 3). While the patients 
were receiving lixisenatide or placebo, pancreati-
tis occurred in 5 patients in the lixisenatide 
group and in 8 in the placebo group; 3 patients 
Figure 2. Mean Glycated Hemoglobin Level, According to Study Visit.
I bars indicate 95% confidence intervals.
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in the lixisenatide group and 9 in the placebo 
group received a diagnosis of pancreatic cancer. 
Systemic allergic reactions occurred in 27 pa-
tients in the lixisenatide group and in 25 in the 
placebo group.
Discussion
In patients with type 2 diabetes and a recent 
acute coronary syndrome, treatment with the 
GLP-1–receptor agonist lixisenatide, added to 
conventional therapy, was not associated with a 
significant difference in rates of cardiovascular 
events as compared with conventional therapy 
plus placebo. This conclusion is supported by 
additional sensitivity analyses that excluded events 
occurring more than 30 days after the discon-
tinuation of lixisenatide or placebo, as well as by 
a post hoc analysis in which the model was ad-
justed for minor between-group imbalances ob-
served at baseline (Table S2 in the Supplemen-
tary Appendix).
This neutral influence of lixisenatide on car-
diovascular end points was reflected in the indi-
vidual components of the primary composite end 
point and was consistent across multiple pre-
specified subgroups. The targeting of a popula-
tion that had type 2 diabetes and a high cardio-
vascular risk due to a recent acute coronary 
syndrome with a protocol that permitted the 
adjustment of glucose-lowering therapies in each 
group, with the expectation of similar glycemic 
control, resulted in modest differences in the gly-
cated hemoglobin level and allowed us to focus on 
cardiovascular actions of the GLP-1–receptor 
agonist that were unrelated to glycemic factors.26
Heart failure is a major cardiovascular burden 
with severe adverse consequences, including a 
substantial increase in the risk of death among 
patients with type 2 diabetes.10,28 Particularly 
worrisome is a meta-analysis of 14 trials of 
glucose-lowering therapies that had enrolled 
more than 95,000 patients with type 2 diabetes 
and showed that both the peroxisome prolifera-
tor-activated receptor and dipeptidyl peptidase-4 
inhibitor (DPP-4) classes of glucose-lowering 
therapies were associated with increased rates of 
heart failure.29
However, subsequent to that analysis, a recent 
major trial showed that the use of sitagliptin 
(another DPP-4 inhibitor) was not associated 
with changes in the rates of hospitalization for 
heart failure.30 Our finding of a neutral effect on 
the incidence of hospitalization for heart failure 
among patients randomly assigned to lixisena-
tide, which was consistent in the subgroups of 
patients with a history of heart failure and those 
without such a history (Table S5 in the Supple-
mentary Appendix), offers new safety informa-
tion regarding this GLP-1–receptor agonist.
Event
Placebo 
(N = 3032)
Lixisenatide 
(N = 3031)
no. of patients with event (%)
Any event 669 (22.1) 625 (20.6)
Blood or lymphatic event 14 (0.5) 14 (0.5)
Cardiac event† 107 (3.5) 83 (2.7)
Ear or labyrinth event 4 (0.1) 5 (0.2)
Endocrine event 3 (0.1) 2 (0.1)
Eye event 13 (0.4) 9 (0.3)
Gastrointestinal event 81 (2.7) 66 (2.2)
General event 58 (1.9) 64 (2.1)
Hepatobiliary event 28 (0.9) 36 (1.2)
Immune system event 2 (0.1) 4 (0.1)
Infection 186 (6.1) 173 (5.7)
Injury or poisoning 50 (1.6) 44 (1.5)
Investigations‡ 19 (0.6) 10 (0.3)
Metabolism or nutrition event 57 (1.9) 33 (1.1)
Musculoskeletal event 35 (1.2) 32 (1.1)
Neoplasm 61 (2.0) 72 (2.4)
Nervous system event 53 (1.7) 47 (1.6)
Psychiatric event 5 (0.2) 9 (0.3)
Renal or urinary event 48 (1.6) 48 (1.6)
Reproductive system event 5 (0.2) 13 (0.4)
Respiratory or thoracic event 58 (1.9) 58 (1.9)
Skin or subcutaneous tissue event 18 (0.6) 14 (0.5)
Social circumstances 0 1 (<0.1)
Surgical or medical procedure 6 (0.2) 6 (0.2)
Vascular event 71 (2.3) 59 (1.9)
*  Events were assessed with the use of the classifications in the Medical Dictionary 
for Regulatory Activities (MedDRA), version 15.0.
†  Adjudicated cardiovascular events were not required to be submitted as serious 
adverse events unless they were considered by the investigator to be possibly 
drug­related.
‡  Investigations included abnormal results on laboratory tests or physical exami­
nation. The most common MedDRA preferred terms used were “alanine amino­
transferase increased” (in seven patients in the placebo group and in two in 
the lixisenatide group) and “blood glucose increased” (in four in the placebo 
group and in one in the lixisenatide group).
Table 3. Serious Adverse Events.*
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Mortality among patients with type 2 diabetes, 
although higher than in the general population, 
varies widely depending on cardiovascular and 
renal coexisting conditions.31,32 The overall an-
nualized mortality in our trial was on the higher 
end of the risk spectrum that has been observed 
in other clinical trials involving patients with 
diabetes. Strides have been made to address the 
nonglycemic risk factors for these patients.33-36
These advances in the standard of care have 
increased the difficulty of showing incremental 
improvements in cardiovascular prognosis with 
intensification of glucose-lowering or lifestyle 
measures.2,37 The few favorable demonstrations 
of reduced rates of cardiovascular events with 
predominantly glucose-lowering therapies have 
required more protracted follow-up than routinely 
occurs in clinical trials.4,7 Although our study 
had only approximately 2 years of follow-up, suf-
ficient numbers of cardiovascular events were 
observed so that we could reasonably exclude a 
major nonglycemic cardiovascular benefit21 as 
well as an unanticipated harm of lixisenatide.
In conclusion, among patients with type 2 
diabetes and a recent acute coronary syndrome, 
treatment with lixisenatide resulted in rates of 
major cardiovascular events, including heart fail-
ure and death from any cause, that were similar 
to those observed with placebo. The neutral car-
diovascular profile associated with lixisenatide 
will inform physicians’ and patients’ decisions 
regarding the use of this agent as an adjunctive 
therapy to control the glycated hemoglobin level 
safely, with no observed augmentation of the 
risks of hypoglycemia or pancreatitis.
Supported by Sanofi.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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